Evidence map›Paper›PMID 32719402›Full record

SynthesisThe ISME journal2020

Multi-omic meta-analysis identifies functional signatures of airway microbiome in chronic obstructive pulmonary disease.

Zhang Wang, Yuqiong Yang, Zhengzheng Yan, Haiyue Liu, Boxuan Chen, Zhenyu Liang, Fengyan Wang, Bruce E Miller, Ruth Tal-Singer, Xinzhu Yi and 8 more

Open access · hybridAbstract readMeta-Analysis
In one paragraph

Synthesis in The ISME journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 5 pooled it
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 5 syntheses or guidelines pooled it, 85 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Microbiota Emergencies in the Diagnosis of Lung Diseases: A Meta-Analysis.Frontiers in cellular and infection microbiology · 2021
    Pooled it
  6. Trial
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Why the COPD Microbiome Matters: How Airway Microbes Shape Disease Severity and Treatment Response.International journal of chronic obstructive pulmonary disease · 2026
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 7 institutions in 4 countries.

Zhang Wang *Institute of Ecological Science, School of Life Science, South China Normal University, Guangzhou, Guangdong Province, China. wangz@m.scnu.edu.cn.ORCID http://orcid.org/0000-0003-1278-8950
Yuqiong Yang *Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong Province, China.
Zhengzheng Yan *State Key Laboratory of Organ Failure Research, Southern Medical University, Guangzhou, Guangdong Province, China.ORCID http://orcid.org/0000-0003-3082-6762
Haiyue LiuState Key Laboratory of Organ Failure Research, Southern Medical University, Guangzhou, Guangdong Province, China.
Boxuan ChenInstitute of Ecological Science, School of Life Science, South China Normal University, Guangzhou, Guangdong Province, China.
Zhenyu LiangGuangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong Province, China.
Fengyan WangGuangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong Province, China.
Bruce E MillerMedical Innovation, Value Evidence and Outcomes, GlaxoSmithKline R&D, Collegeville, PA, USA.
Ruth Tal-SingerMedical Innovation, Value Evidence and Outcomes, GlaxoSmithKline R&D, Collegeville, PA, USA.
Xinzhu YiInstitute of Ecological Science, School of Life Science, South China Normal University, Guangzhou, Guangdong Province, China.
Jintian LiInstitute of Ecological Science, School of Life Science, South China Normal University, Guangzhou, Guangdong Province, China.
Martin R StampfliDepartment of Medicine, Firestone Institute of Respiratory Health at St. Joseph's Healthcare, McMaster University, Hamilton, ON, Canada.
Hongwei ZhouState Key Laboratory of Organ Failure Research, Southern Medical University, Guangzhou, Guangdong Province, China.ORCID http://orcid.org/0000-0003-2472-8541
Christopher E BrightlingInstitute for Lung Health, Leicester NIHR Biomedical Research Centre, Department of Respiratory Sciences, University of Leicester, Leicester, UK.
James R BrownHuman Genetics, GlaxoSmithKline R&D, Collegeville, PA, USA.ORCID http://orcid.org/0000-0002-9368-627X
Martin WuDepartment of Biology, University of Virginia, Charlottesville, VA, USA.
Rongchang ChenGuangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong Province, China.
Wensheng ShuInstitute of Ecological Science, School of Life Science, South China Normal University, Guangzhou, Guangdong Province, China.
South China Normal University · CNFirst Affiliated Hospital of Guangzhou Medical University · CNGlaxoSmithKline (United States) · USSouthern Medical University · CNSt. Joseph’s Healthcare Hamilton · CAUniversity of Leicester · GBUniversity of Virginia · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The interaction between airway microbiome and host in chronic obstructive pulmonary disease (COPD) is poorly understood. Here we used a multi-omic meta-analysis approach to characterize the functional signature of airway microbiome in COPD. We retrieved all public COPD sputum microbiome datasets, totaling 1640 samples from 16S rRNA gene datasets and 26 samples from metagenomic datasets from across the world. We identified microbial taxonomic shifts using random effect meta-analysis and established a global classifier for COPD using 12 microbial genera. We inferred the metabolic potentials for the airway microbiome, established their molecular links to host targets, and explored their effects in a separate meta-analysis on 1340 public human airway transcriptome samples for COPD. 29.6% of differentially expressed human pathways were predicted to be targeted by microbiome metabolism. For inferred metabolite-host interactions, the flux of disease-modifying metabolites as predicted from host transcriptome was generally concordant with their predicted metabolic turnover in microbiome, suggesting a synergistic response between microbiome and host in COPD. The meta-analysis results were further validated by a pilot multi-omic study on 18 COPD patients and 10 controls, in which airway metagenome, metabolome, and host transcriptome were simultaneously characterized. 69.9% of the proposed "microbiome-metabolite-host" interaction links were validated in the independent multi-omic data. Butyrate, homocysteine, and palmitate were the microbial metabolites showing strongest interactions with COPD-associated host genes. Our meta-analysis uncovered functional properties of airway microbiome that interacted with COPD host gene signatures, and demonstrated the possibility of leveraging public multi-omic data to interrogate disease biology.

Indexed as

MicrobiotaPulmonary Disease, Chronic ObstructiveHumansMetagenomeRNA, Ribosomal, 16SSputumRNA, Ribosomal, 16S

Identifiers

PMID32719402
PMCPMC7784873
OpenAlexW3044875548

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.